Actively Recruiting
Shorter Versus Extended Course of Antibiotic Therapy for Necrotizing Soft Tissue Infections
Led by University of California, Irvine · Updated on 2026-02-10
50
Participants Needed
1
Research Sites
152 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Necrotizing soft tissue infection (NSTI) is a devastating disease that results in a high rate of in-hospital complications and despite advances in critical care, wound care, and early intervention, NSTI continues to be associated with a mortality rate of nearly 30%. The antibiotics used in this treatment are Clindamycin, Vancomycin, Piperacillin Tazobactam; these antibiotics may be administered combined or individually, based on individualized patient treatment. Although one of the tenets of management for NSTI is early broad-spectrum intravenous antibiotics (listed above), the duration of antibiotics needed is not well defined. Currently, there exists wide variation in the duration of antibiotics for NSTI ranging between 2-16 days. The objective of this study is to evaluate the safety of a shorter course of antibiotics hypothesizing that a short duration of antibiotics for 48-hours after source-control is achieved will have similar risk of morbidity and mortality compared to a 7-day course of antibiotics post source control. A second aim of this study will be to identify if serum procalcitonin levels/ratio correspond to resolution of systemic infection in patients with NSTI.
CONDITIONS
Official Title
Shorter Versus Extended Course of Antibiotic Therapy for Necrotizing Soft Tissue Infections
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients 18 years or older
- Presenting to the Emergency Department with signs or imaging suggesting NSTI
- Consulted by the Emergency General Surgery service
- Have skin or soft tissue signs consistent with NSTI such as erythema, crepitus, or severe pain
- Show systemic infection signs including fever above 38.0°C or high white blood cell count (≥11,000/mm3)
- Underwent excisional debridement and/or amputation for source control
You will not qualify if you...
- Pregnant patients
- Prisoners
- Patients with bacteremia at admission
- Patients unable to provide consent or without a legally authorized representative
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of California Irvine Medical Center
Orange, California, United States, 92868
Actively Recruiting
Research Team
A
Areg Grigorian, MD
CONTACT
J
Jeffry Nahmias, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here